IL4 and asthma: Monoclonal antibodies directed against IgE, IL-4 and 13 and IL-5 have been extensively studied in asthma, and one anti-IgE and two anti-IL-5 monoclonal antibodies have been approved by the US FDA for the treatment of severe asthma [27, 28].